Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia

GlobeNewswire December 4, 2017

Ultragenyx to Highlight Pipeline at Analyst and Investor Day on December 4

GlobeNewswire November 30, 2017

Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire November 16, 2017

Ultragenyx Announces FDA Approval of MEPSEVII™ (vestronidase alfa), the First Therapy for Progressive and Debilitating Rare Genetic Disease Mucopolysaccharidosis VII

GlobeNewswire November 15, 2017

Thinking about buying Acorda Therapeutics, JA Solar, Ultragenyx Pharmaceuticals, Square Inc. or Target?

PR Newswire November 15, 2017

Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate

Benzinga.com  November 15, 2017

Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics

GlobeNewswire November 7, 2017

Ultragenyx to Present at the Credit Suisse Healthcare Conference

GlobeNewswire November 6, 2017

Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate Update

GlobeNewswire November 2, 2017

Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold Advisory Committee Meeting for Burosumab Biologics License Application

GlobeNewswire November 1, 2017

Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon

Benzinga.com  October 31, 2017

Ultragenyx to Host Conference Call for Third Quarter 2017 Financial Results and Corporate Update

GlobeNewswire October 30, 2017

Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx’s Acquisition of Dimension

GlobeNewswire October 26, 2017

WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders

PR Newswire October 13, 2017

Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application

GlobeNewswire October 10, 2017

Wall Street's M&A Chatter From October 2: Kroger, ILG, Methode Electronics-Pacific Insight, Ultragenyx-Dimension

Benzinga.com  October 4, 2017

Ultragenyx to Acquire Dimension Therapeutics

GlobeNewswire October 3, 2017

Ultragenyx Comments on Dimension Therapeutics’ Announcement that Ultragenyx’s Offer is a “Superior Proposal” 

GlobeNewswire October 2, 2017

REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics

GlobeNewswire October 2, 2017

Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”

GlobeNewswire October 2, 2017